Literature DB >> 576822

Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard.

B Spiegelhalder, M Eichelbaum.   

Abstract

In the present investigation a mass fragmentographic procedure for the quantitative determination of verapamil in human plasma was developed which makes use of the principle of mass spectrometry and of isotopic dilution: a known amount of isotopically labelled standard ([13C, 2H2]-verapamil) is added to the plasma sample. After an effective extraction procedure the ratio of the main fragments of verapamil (m/e 303) and the labelled standard (m/e 306) is measured by mass fragmentography. The lower limit of detection is at 1 ng/ml for plasma and at 10 pg/injection for pure verapamil. The precision was found to be between 3.4% and 14.4%, depending on the range (32.7 ng/ml and 2.2 ng/ml, resp.) of the concentration of verapamil in plasma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 576822

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  17 in total

1.  Unreviewed reports.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

2.  Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.

Authors:  M Eichelbaum; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Level of verapamil in human milk.

Authors:  H Inoue; N Unno; M C Ou; Y Iwama; T Sugimoto
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response.

Authors:  M Eichelbaum; M Albrecht; G Kliems; K Schäfer; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

5.  Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.

Authors:  M Eichelbaum; P Birkel; E Grube; U Gütgemann; A Somogyi
Journal:  Klin Wochenschr       Date:  1980-09-15

6.  Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.

Authors:  M Eichelbaum; A Somogyi; G E von Unruh; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

7.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

8.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

Authors:  M Eichelbaum; G Mikus; B Vogelgesang
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Fatal poisoning with verapamil.

Authors:  H P Gelbke; H J Schlicht; G Schmidt
Journal:  Arch Toxicol       Date:  1977-06-18       Impact factor: 5.153

Review 10.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.